Trius Therapeutics — Technical Presentation (March 2013)
15 slides from Trius Therapeutics's technical presentation, Mar 25, 2013
Slide 1: The Future of Anti-Infectives: ESTABLISH 2 Top Line Data Release
The Future of Anti-Infectives ESTABLISH 2 Top Line Data Release March 25, 2013 Exhibit 99.2
Slide 2: Forward Looking Statements
Forward Looking Statements Statements contained in this data release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual res
Slide 3: ESTABLISH 2 (IV/PO) Phase 3 Trial Design
2 o EMA 1 o EMA 1 o FDA 2 o FDA ESTABLISH 2 (IV/PO) Phase 3 Trial Design Tedizolid Linezolid 1x 200mg 2x 600mg n=666 Placebo Post-Treatment Evaluations END-POINTS FOR GLOBAL REGISTRATION Safety Analysis Non-inferiority trial design vs. Linezolid
Slide 4: ESTABLISH 2 Demographics and Baseline Characteristics
Tedizolid, % n = 332 Linezolid , % n = 334 ESTABLISH 2 Demographics and Baseline Characteristics Male, % 67.8 64.1 Age, mean 45.6 45.6 Geographic Region, % North America (US) 47.0 47.3 Ex-U.S. 53.0 52.7 Clinical Syndrome, % Cellulitis/erysipelas 50.0 50.3 Major abscess 20.5 20.4 Wound infection 29.5
Slide 5: ESTABLISH 2 Efficacy
ITT Analysis Set Endpoint Tedizolid 6 days treatment, % n = 332 Linezolid 10 days treatment, % n = 334 Treatment Difference (95% CI), % Primary Endpoint Key Secondary Endpoints Sensitivity analysis (2010 FDA Guidance) ESTABLISH 2 Efficacy >20% decrease from baseline in lesion area at 48-72 hours 85.
Slide 6: ESTABLISH 2 Efficacy by Infection Type
ITT Analysis Set Tedizolid 6 days treatment, % n = 332 Linezolid 10 days treatment, % n = 334 Treatment Difference (95% CI), % Cellulitis/erysipelas Major cutaneous abscess Wound infection ESTABLISH 2 Efficacy by Infection Type 80.7 n = 166 80.4 n = 168 0.37 (-8.2 to 8.9) 86.8 n = 68 89.7 n = 68 -2.
Slide 7: Safety: Tedizolid was Safe and Well Tolerated with a Favorable AE Profile vs. Linezolid
Safety Analysis Set Tedizolid 6 days treatment, % Linezolid 10 days treatment, % Any Treatment Emergent Adverse Event (TEAE) Any Drug Related TEAE Gastrointestinal Disorders ESTABLISH 2 Safety: Tedizolid was Safe and Well Tolerated with a Favorable AE Profile vs. Linezolid 45.3 43.7 20.5 24.8 16.0 2
Slide 8: ESTABLISH 2 Incidence of TEAEs >2%
System Organ Class Tedizolid, (%) n = 331 Linezolid, (%) n =327 ESTABLISH 2 Incidence of TEAEs >2% Gastrointestinal disorders 53 (16.0) 67 (20.5) General disorders and administration site conditions 23 (6.9) 24 (7.3) Infections and infestations 40 (12.1) 40 (12.2) Metabolism and nutrition disorders
Slide 9: ESTABLISH 2 Post-Baseline Substantially Abnormal Hematology Values
Tedizolid, (%) n = 331 Linezolid, (%) n =327 ESTABLISH 2 Post-Baseline Substantially Abnormal Hematology Values Hemoglobin Below LLN 147 (50.3) 148 (51.6) Substantially abnormal 4 (1.4) 2 (0.7) White blood cells Below LLN 16 (5.9) 20 (7.8) Substantially abnormal 3 (1.1) 5 (1.9) Platelets Below LLN 3
Slide 10: Differences Between ESTABLISH 1 and 2
ESTABLISH 2 ESTABLISH 1 Dosing Demographics MRSA, % Primary Endpoint* Differences Between ESTABLISH 1 and 2 IV to oral (minimum st day’s dosing IV) Oral US 47%, x-US 53% US 80%, x-US 20% 27.1 42.6 > 20% reduction in lesion area @ 48 to 72 hours Cessation of lesion spread, absence of fever @ 48 to 72
Slide 11: ESTABLISH Program Comparison
Endpoint Study Tedizolid 6 days treatment, % Linezolid 10 days treatment, % Treatment Difference (95% CI), % >20% decrease from baseline in lesion area at 48-72 hours Sustained clinical response at end of therapy Investigators assessment of clinical response at 7- 14 days after end of therapy Cessat
Slide 12: ESTABLISH Program Safety Comparison
Safety Analysis Set Study Tedizolid % Linezolid % Any Treatment Emergent Adverse Event (TEAE) Any Drug Related TEAE Gastrointestinal Disorders ESTABLISH Program Safety Comparison ESTABLISH 2 45.3 43.7 ESTABLISH 1 40.8 43.3 ESTABLISH 2 20.5 24.8 ESTABLISH 1 24.2 31.0 ESTABLISH 2 16.0 20.5 ESTABLISH 1
Slide 13: Strong Response to Tedizolid Efficacy, Dosing and Administration
Tedizolid, 65% Tedizolid, 52% Zyvox, 62% Zyvox, 42% Cubicin, 54% Cubicin, 37% Vancomycin, 25% Vancomycin, 27% Tedizolid, 45% Tedizolid, 42% Zyvox, 45% Zyvox, 38% Cubicin, 42% Cubicin, 37% Vancomycin, 30% Vancomycin, 30% *Efficacy performance ratings among those aware of brand Tedizolid ATU Study, Wa
Slide 14: Strong Response to Tedizolid Safety & Tolerability
Tedizolid, 48% Tedizolid, 53% Tedizolid, 59% Zyvox, 27% Zyvox, 45% Zyvox, 31% Cubicin, 48% Cubicin, 42% Cubicin, 44% Vancomycin, 39% Vanco ., 14% Vancomycin, 25% Strong Response to Tedizolid Safety & Tolerability Has a low frequency of DDI (drug-drug interaction) Does not cause renal and hepatic imp
Slide 15: Physician Interest in Tedizolid Strong Across Specialties
80% 69% 74% 72% 76% 92% 83% 19% 31% 25% 27% 23% 7% 17% Tedizolid ATU Study, Wave – USA Report, conducted by CMI on behalf of Trius, November 2012, N=505 Base: Total respondents Q8.1 How interesting is tedizolid to you for suspected or confirmed MRSA ABSSSI patients overall? Use a to scale where “1”
Trius Therapeutics — Technical Presentation (March 2013) on 6ix